Moreover, at 10 nmol/L, ibrutinib and acalabrutinib very effectively suppress BTK-mediated induction of CD69 expression, including following anti-IgM stimulation of CLL cells [37, 41] and ibrutinib and acalabrutinib effectively inhibit anti-IgM-induced downstream phospholipase C gamma 2 (PLCγ2) phosphorylation in B-cell lines and CLL cells (Arthur et al., manuscript in preparation). Here, CD40LG is linked to B-cell chronic lymphocytic leukemia.